Tenderwize
Back to tender search

Non-exclusive Rebate Agreement for Tacrolimus

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Oct 31, 2027 · 435 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tacrolimus (ATC-Code nach WHO: D11AH01)

30/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

30 / 100

Complexity

30 / 100

Risk factors

No minimum volume or purchase commitment; actual demand is uncertain and dependent on prescribing behavior and pharmacy...

The contracting authority may terminate the open-house procedure early if exclusive agreements are signed, ending exist...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Supply of pharmaceutical products containing Tacrolimus (ATC D11AH01)
  • Non-exclusive rebate agreement with AOK PLUS
Show full summary

This tender is for non-exclusive pharmaceutical rebate agreements under an open-house model for the active substance Tacrolimus (ATC D11AH01), organized by AOK PLUS. It is not a formal public procurement but is published for transparency. Any qualified pharmaceutical company can join during the participation period, with the first deadline on 7 October 2025 and subsequent deadlines until 31 October 2027. Contract ends no later than 31 October 2027. No exclusivity, no minimum volume, and no guarantee of purchases. The rebate terms are confidential. Award is based solely on meeting participation conditions.

Risks

No minimum volume or purchase commitment; actual demand is uncertain and dependent on prescribing behavior and pharmacy...

The contracting authority may terminate the open-house procedure early if exclusive agreements are signed, ending exist...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical company as defined in §4(18) AMG

Eligibility

  • Must provide self-declaration of no exclusion grounds (Sections 123, 124 GWB)

Administrative

  • Must provide declaration regarding Russia sanctions

Requirements may be incomplete.

Buyer

Location

Erfurt, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive Rebate Agreement for Tacrolimus

Non-exclusive rebate agreement for Tacrolimus (ATC D11AH01) under an open-house model. Any pharmaceutical company fulfilling conditions can join. No minimum volume or exclusivity. Contract period from 7 October 2025 to 31 October 2027.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Oct 2025 - Oct 2027

Category

Pharmaceutical products

Deadline

Deadline Oct 31, 2027

Procurement Details

Publication date
28 Aug 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
565111-2025

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3